MEDI4736 Combinations in Metastatic Renal Cell Carcinoma

NCT02819596 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Renal Clear Cell Carcinoma
Renal Papillary Cell Carcinoma

Interventions

DRUG: Savolitinib
DRUG: MEDI4736
DRUG: Tremelimumab

Sponsor

Queen Mary University of London

Collaborators

[object Object]
[object Object]